CTLA4 and pneumonitis: Pneumonitis as an immune-related adverse event (irAE) affects almost 5% of patients receiving anti-PD-1/PD-L1 in monotherapy and approximately 10% in anti-CTLA-4/anti-PD-1 combination therapy [17], rarely leading to death [18].